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Abstract
Asthma results from exposure to allergens and other airway irritants. While clinical
treatment of the disease has recently expanded beyond simply β-agonists and inhaled
steroids, recent strategies seeking to modulate the immune mechanisms of the disease
have offered incomplete control of the disease. This study demonstrates a
mechanistically novel component in the development of asthmatic inflammation
mediated by sensory neurons within the lung parenchyma. Sensory neurons are rich in
the transient receptor potential channel A1 (TRPA1), an ion channel activated by strong
triggers of asthma, including cigarette smoke, chlorine, and hypochlorite. This project
examines the role of TRPA1 in the development of allergic inflammation in an
ovalbumin-based murine model of asthma. All quantifiable measures of asthmatic
inflammation including airway hyperreactivity, mucus production, and cytokine
production were significantly reduced by both genetic deletion and pharmacological
blockade of TRPA1. This finding suggests not only that TRPA1 is a mechanistically
important factor in the development of allergic inflammation, but it also offers a new
potential pharmacological target in the treatment of asthma.
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Introduction
The rate of asthma in the United States and world-wide has increased significantly
throughout the past decades [1, 2]. An estimated 9.2% of American children, and a
global total of 300 million people, are affected by the condition [3], which is particularly
concerning due to the potential for severe exacerbations that may be life-threatening.
The inflammatory response of asthma is characterized by a CD4 Th2 cell
mediated infiltration of eosinophils, mast cell activation and, ultimately, tissue
remodeling. Mucus hyperplasia and airway hyper reactivity are also characteristic [4].
Mast cells infiltrate the surrounding smooth muscle, [5] and the generalized inflammatory
response eventually leads to airway remodeling, including smooth muscle hyperplasia
and collagen deposition below the epithelial basement membrane [6].
Current treatment of asthma is largely focused on two classes of medications:
bronchodilators and corticosteroids. These function to relax the smooth muscle of the
airway as β2-adrenergic agonists and through eliminating airway inflammation,
respectively. Each of these medication classes carries with it associated side effects. β2adrenergic agonists produce dose-dependent tremor, tachycardia, and anxiety, and
corticosteroids most commonly cause cough, vocal hoarseness, sore throat and
predisposition to thrush. At high doses, corticosteroids can cause growth retardation [7],
cataracts [8], elevated intraocular pressures, and bone loss [9]. Furthermore,
corticosteroids merely suppress asthmatic inflammation. Discontinuation of steroids
results in the return to baseline levels of asthmatic inflammation, eosinophilc infiltration,
and bronchial hyperreactivity within 2 weeks [10]. While asthma related hospitalizations
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and deaths in the United States have decreased over the past 30 years with the use of
these and other medications [11], there remains room for improvement in current
therapies. Novel approaches to the treatment of asthma focus on immune modulation,
but these treatments are not considered first-line.
Novel drugs are needed to target and reduce inflammation. Sensory nerves within
the lung parenchyma can mediate inflammation. Sensory neurons richly innervate the
lung and are sensitive to noxious stimuli in the air [12], and recent evidence indicates that
there is likely bidirectional feedback between immunogenic and neurogenic mechanisms
of inflammation [13, 14]. Furthermore, neuronal activation induces many of the
symptoms of asthma including inflammation, mucus hypersecretion, cough and
bronchoconstriction [15, 16]. Nerve endings present in the nasal mucosa are the
outermost detection point for noxious chemicals. Stimulation of these sensory neurons
causes pain and sneezing [17]. These sensory nerves release neuropeptides including
substance P and CGRP in response to noxious stimuli. These proinflammatory
neuropeptides promote structural changes in the microvascular endothelium leading to
edema formation and narrowing of the nasal airway [18, 19]. Stimulation of vagal
sensory fibers in the glottis and larynx leads to coughing and the expulsion of noxious air.
Irritants not expelled by the coughing reflex enter the lower airways and cause
neurogenic inflammation, mucus secretion and airway hyperreactivity. In addition to
these changes, inhaled irritants elicit other specific physiological responses. For example,
rodents can decrease their respiratory rate by up to 50% in response to irritant exposure
[20].
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TRPA1 is a sensory ion channel expressed in approximately one-third of sensory
neurons [21, 22]. While initial studies identified TRPA1 as the receptor for mustard oil
(allyl isothiocyanate), further investigation identified additional agonists including
cinnamic aldehyde, isovelleral, and diallyl sulfides [23-25]. Administration of any of
these TRPA1 agonists to the skin causes pain, hyperalgesia and neurogenic inflammation
[26, 27].
Early evidence suggests that TRPA1 is a possible airway irritant receptor. Prior
to the identification of TRPA1, studies demonstrated that airway irritants led to calcium
influx into sensory nerves [28]. Not only is TRPA1 a calcium-permeable channel, but
pretreatment with ruthenium red, a non-specific Ca2+ channel blocker blocker, prevents
bronchoconstriction in response to inhaled irritants [29-31]. Additionally, allyl
isothiocyanate, a TRPA1 agonist, is a widely known upper airway irritant because it is
the “active” ingredient of wasabi [32].
Following these preliminary suggestions of the role of TRPA1 in detection of
airway irritants, Bautista et al. identified that acrolein, a highly irritating unsaturated
aldehyde present in smoke, activated TRPA1[32]. Significantly, Trpa1-/- mice did not
respond to this irritant by characteristically lowering their respiratory rates.
The role of TRPA1 in irritant detection expanded with the finding that it is
responsible for detecting oxidants including ozone, hypochlorite, and chlorine gas [33].
This study found that neurons of the trigeminal and nodose ganglia, which innervate the
lower airways, express TRPA1 and are responsible for irritant induced hyperreactivity.
HC-030031, a TRPA1 selective antagonist, was subsequently found to eliminate
neuropeptide-mediated bronchoconstriction in harvested guinea pig lungs in response to
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exposure to unsaturated aldehydes [34]. HC-030031was shown in the same study to
abolish neurogenic inflammation secondary to tobacco smoke. Taken together, these
early studies have demonstrated that TRPA1 is responsible for detection of noxious
stimuli including unsaturated aldehydes, hypochlorite, isocyanates and tobacco smoke.
In response to these stimuli, TRPA1 activation leads to release of neuropeptides
responsible for neurogenic inflammation and airway hyperreactivity.
Activation of TRPA1 is believed to occur via covalent modification of a cytosolic
region of the channel [35, 36]. Known TRPA1 agonists, including unsaturated
aldehydes, isothiocyanates, and oxidants are inherently reactive. Isothiocyanates likely
form thiourea adducts with cysteine residues of the channel [35]. Unsaturated aldehydes
react with cysteine residues through a Michael Addition and react with lysine and
histidine residues to form Schiff bases. Oxidant agonists oxidize the thiol moiety of
cysteines [37]. The finding that irreversible covalent modification of the channel can
lock TRPA1 in an activated position allowed for the localization of the region of the
channel sensitive to modification by an agonist. Using systematic mutagenesis replacing
potential sites of covalent modification by allyl isothiocyanate with unreactive amino
acids, a group of cysteine and lysine residues were identified at the cytosolic N-terminus
that are responsible for channel activation [35]. Even though nearly every cytosolic
cysteine residue was covalently modified during isothiocyanate treatment, blocking
covalent modification at this specific region prevented activation [36]. Interestingly, the
same residues are responsible for activation of TRPA1 by unsaturated aldehydes and
oxidants [38-39]. Irreversible covalent modification and subsequent constant activation
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of TRPA1 offers an explanation of the continued post-exposure irritation reported by
individuals exposed to known TRPA1 agonists including tear gas and hypochlorite [39].
TRPA1 activity is not limited to exogenous activators. Oxidative stress produces
numerous TRPA1 activators including reactive oxygen species (ROS), hypochlorite, and
lipid peroxidation products. Oxidative stress, which produces these compounds, is
present in airway inflammation caused by asthma, COPD, rhinitis, and viral infection
[40-42]. Macrophages and neutrophils produce ROS during inflammation [43, 44] many
of which activate TRPA1 [45]. For example, hypochlorite concentrations in the
interstitial spaces during airway inflammation far the EC50 of TRPA1[39, 46]. In
addition to the effects of ROS alone, these highly reactive compounds damage cell
membranes creating lipid peroxidation products [47]. Lipid peroxidatioon products
themselves are known agonists of TRPA1 in both heterologous expression systems and in
vivo [45, 48-51]. One endogenous TRPA1 agonist with greatest in vivo effect has not
been identified, and it is possible that a complex mixture of reactive species all activate
TRPA1.
Taken together, this evidence suggests that the transient receptor potential (TRP)
ion channel superfamily is involved in the response to inflammatory mediators [51-53].
Through TRP channels, sensory neurons are activated by ozone, chlorine, capsaicin, and
acrolein. Each of these compounds has been linked to the development of reactive
airway dysfunction syndrome [53-57]. Mustard oil, cinnamon oil, and wintergreen oil
selectively activate TRPA1. Additionally, TRPA1 is activated by bradykinin through the
action of a G-protein coupled receptor [58-60]. Moreover, reactive oxygen species and
lipid peroxidation products are potentially significant endogenous activators of TRPA1
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[61-63] making TRPA1 a likely player in the development of inflammation. In fact,
blockade of TRPA1 reduces inflammatory hyperalgesia and decrease airway
hyperreactivity in mice with chemically induced inflammation [55, 64].
Our work identifies TRPA1 as an important part of the development of
experimentally-induced acute asthma. TRPA1 is important in inducing the release of
neuropeptides, which leads to increased leukocyte infiltration, mucus hyper-production,
and airway hyperreactivity. Animals with either genetically deleted or pharmacologically
blocked TRPA1 do not generate the same response. Furthermore, while another member
of the TRP superfamily, TRPV1, is a well-known proinflammatory channel expressed in
sensory neurons, the development of experimentally induced asthma is not dependent
upon this channel.
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Specific Aims
1. Demonstrate the role of TRPA1 in the development of acute asthma in an OVA-based
murine model
2. Demonstrate the ability of pharmacologic blockage or genetic deletion to reduce
quantifiable measures of allergic inflammation including: airway hyperreactivity, mucus
production, cell extravasation, and neuropeptide release.

10

Methods
Animals. Experimental procedures were approved by the Institutional Animal Care and
Use Committees of Yale University, the University of California, San Francisco, and
Hydra Biosciences. Mice were housed at facilities accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care in standard environmental
conditions (12-h light-dark cycle and 23 °C). Food and water were provided ad libitum.
Trpa1-/- mice were a gift from David Julius (University of California, San Francisco).
The Trpa1 knockout allele was backcrossed into the C57BL/6 background (>99.5%) by
marker assisted accelerated backcrossing (Charles River Laboratories). Trpv1-/- mice
were purchased from Jackson Laboratories and C57/Bl6 and BALB/c mice from Charles
River Laboratories. For experiments on C57BL/6, Trpv1-/-, and Trpa1-/- mice, animals
were matched for age (12–22 weeks) and gender. Six- to 8-week-old BALB/c mice were
used for OVA sensitization and antagonist studies.

Measurement of Airway Reactivity. Twenty-four hours following the last OVA
challenge, mice were anesthetized with pentobarbital (60 mg/kg of body weight) and
urethane (1 g/kg). A tracheostomy was performed, and the trachea was cannulated by Dr.
Caceres. Mice were attached to a Flexivent pulmonary mechanics analyzer (SCIREQ)
and ventilated at a tidal volume of 9 mL/kg, at a frequency of 150 bpm. Positive endexpiratory pressure was set at 2 cm H2O. Mice were paralyzed with pancuronium (0.1
mg/kg i.p.). A 27-gauge needle was used to administer acetylcholine (0.03, 0.1, 0.3, 1.0,
and 3.0 mg/mL) through the subclavian vein to generate a concentration-response curve.
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Measurements of airway mechanics were made continuously applying the singlecompartment model.

Quantitative Real-time PCR. Lungs and DRGs were surgical removed and white cells
were collected from BAL by centrifugation. CD4 Th2 cells were purified as previously
described [65]. Tissue and cells were frozen in liquid nitrogen. Total RNA was isolated
from tissue homogenates using RNeasy Mini Kit 50 (Qiagen). cDNA synthesis was
performed with the High Capacity RNA-to-cDNA Kit (Applied Biosystems).
Quantitative PCR was performed using TaqMan Gene Expression Assays (Applied
Biosystems). Typically, 20-μL reactions contained 10 μL TaqMan Fast Universal PCR
Master Mix (2X), 1 μL of the specific TaqMan assay, 1 μL cDNA, and water to 20 μL.
Cycling parameters were 52 °C for 2 min for activation and 10 min initial setup at 95 °C,
followed by 40 cycles of 95 °C for 15 s and 1 min at 60 °C (ABI 7500 Fast, Applied
Biosystems). Each sample was run in triplicate and normalized to GADPH gene
expression. CT values were determined using ABI PRISM software and averaged.
Relative quantification was determined by the ΔΔCT method [66]. The TaqMan Gene
Expression Assays included specific primers and FAM/MGB probes for mGAPDH
[endogenous Control (4352932E)], mTRPA1 (Mm00625268_m1), mMucin 5 subtypes A
and C (Mm01276735_m1), and mIL-5 (Mm99999063_m1).

Data Analysis and Statistics. Data were analyzed using Origin 8 (OriginLab Corp.) and
SPSS (SPSS Inc.) software. Cell differentials and qPCR data were analyzed by Student’s
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t-test for independent samples. Airway forced oscillation data were analyzed by repeatedmeasures ANOVA, followed by Bonferroni post-hoc analysis.
Note: All animal handling, sensitization with OVA, and cytokine analysis was done
by Dr. Caceres. Airway reactivity studies were a cooperative effort between Ana
Caceres, Maxwell Elia, and Bret Bessac. Maxwell Elia performed all qPCR
experiments.
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Results

Figure 1: OVA Model of Allergic Asthma
Mice were sensitized with 50µg ovalbumin/2mg alum IP once per week for 3 doses. The
mice were then given one week of rest after which they were given 3 intranasal
administrations of 100µg ovalbumin/40µl PBS on consecutive days. Animals treated with
HC-030031 were given 200mg/kg on day 20, and subsequently given 100mg/kg twice
daily until sacrifice.

Diminished Leukocyte Infiltration in OVA-Challenged Trpa1-/- Mice.
Ovalbumin (OVA) was used to generate a Th2-directed allergic response. The OVA
model was optimized by monitoring the leukocyte numbers in the bronchoalveolar lavage
fluid (BALF) of wild-type C57BL/6 mice. Marked increases in eosinophils in BALF of
wild-type mice were noted in response to OVA. This increase in response to OVA
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challenge was blunted in Trpa1-/- mice. Trpa1-/- mice showed an 80% reduction in
eosinophils in BALF. Interestingly, the cell counts of OVA challenged Trpv1-/- mice
were indistinguishable from those of wild-type mice.

Figure 2: Reduced Cell infiltration in Trpa1-/- mice. Cell differentials from BALF
from mice with and without OVA challenge. Animal groups: Trpa1+/+ OVA: n = 8,
Trpa1-/- OVA: n = 8, Trpa1 +/+ veh: n = 7, Trpa1-/- veh: n = 6. *, P < 0.05; **, P < 0.01;
***, P < 0.001 .

Diminished Airway Hyperreactivity in OVA-Challenged Trpa1-/- Mice.
Bronchoconstriction is a significant symptom of asthma. Forced oscillation
plethysmography in response to i.v. administration of increasing concentrations of
acetylcholine was used to assess airway hyperreactivity.
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Figure 3: Reduced Airway Hyperreactivty in Trpa1-/- mice. Airway resistance as
measured by Flexivent pulmonary mechanics analyzer. Animal groups: Trpa1+/+ OVA:
n = 4, Trpa1-/- OVA: n = 4, Trpa1 +/+ veh: n = 7, Trpa1-/- veh: n = 6. (*, α = 0.05;
**, α = 0.01; ***, α = 0.001).

The difference in airway resistance between OVA-challenged Trpa1-/- was minimal
compared to unchallenged mice. This confirms the necessary role of TRPA1 function in
the asthmatic hyperreactivity.

Reduced Mucus Production in OVA-Challenged Trpa1-/- Mice.
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Mucin is a widely expressed component of mucus, which is overproduced in asthmatics.
Mucin transcription is a quantifiable measure of mucus hypersecretion, so mucin
transcription was measured by qPCR to compare mice with and without OVA-challenge.

Figure 4: Impaired induction of Mucin Transcription in Trpa1-/-, but not Trpv1-/mice in response to OVA-challenge. Relative quantities (RQ) of mucin5ac gene
transcript, determined by qPCR of whole mouse lung cDNA. Mucin5ac induction is
diminished in Trpa1-/- OVA mice. GAPDH transcript levels were used for normalization
as endogenous control. Animal groups: Trpa1+/+ OVA: n = 4, Trpa1-/- OVA: n = 4,
Trpa1 +/+ veh: n = 6, Trpa1-/- veh: n = 7. Trpv1 studies: n = 4 mice per group.
*, P < 0.05

Induction of mucus production as a result of OVA-challenge is blunted in the Trpa1-/mice. In contrast, the expression mucin among Trpv1 -/- mice is the same as among
wild-type mice further supporting the sole role of TRPA1 in the development of
asthmatic inflammation.
17

Reduced Th2-Cytokine Transcription in Airways of OVA-Challenged Trpa1-/Mice.
Interleukin 5 (IL-5) is a marker for Th2 mediated inflammation. Comparison of
transcription of this cytokine allows for a meaningful, quantitative comparison of
inflammation between the groups of mice. No transcriptional difference of IL-5 was
noted between Trpa1-/- OVA-challenged mice and control animals whereas Trpv1-/OVA-challenged mice had no such evidence of a blunted Th2 immune response.

Figure 5: Decreased IL-5 transcription in Trpa1-/-, but not Trpv1-/-, mice in
response to OVA-challenge. Relative quantities (RQ) of Interleukin 5 (IL-5) gene
transcript, determined by qPCR of whole mouse lung cDNA. IL-5 is massively reduced
in Trpa1-/- OVA-challenged mice. GAPDH transcript levels were used for normalization
as endogenous control. Animal groups: Trpa1+/+ OVA: n = 4, Trpa1-/- OVA: n = 4,
Trpa1 +/+ veh: n = 6, Trpa1-/- veh: n = 6. ***, P < 0.001. Trpv1 studies: n = 4 mice per
group.
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Previous ELISAs performed by Dr. Caceres found undetectable levels of INF-γ in all
animal groups eliminating the possibility that the Trpa1-/- mice had a Th1 immune
response as a result of the OVA-challenge.

TRPA1 Antagonist (HC-030031) Reduces Airway Hyperreactivity when
Administered During OVA Airway Challenge.
HC-030031 has been shown to pharmacologically block TRPA1 and prevent
inflammatory pain in animals treated with TRPA1 agonists [56, 64, 67]. HC-030031 was
administered via intraperitoneal injection to Balb/C mice during the airway challenge
phase of the OVA-model. The administration schedule of the drug was: the day before
(200 mg/kg) and twice daily (100 mg/kg) during the 4 days of OVA airway challenge.
Control mice were administered methyl cellulose (MC) on the same schedule. Similar to
mice with genetic deletion of TRPA1, OVA-challenged Balb/C mice treated with HC030031 show near elimination of lung hyperreactivity.
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Figure 6: Reduced Airway Hyperreactivty in OVA-challenged mice treated with
i.p. HC-030031.
Airway resistance as measured by Flexivent pulmonary mechanics analyzer for mice
treated with either HC-030031 or with just methyl cellulose (MC). MC veh: n = 7, HC030031 veh: n = 7, MC OVA, n = 7, HC-030031 OVA: n = 6
(**, α = 0.01; ***, α = 0.001)

Reduced Mucus Production in OVA-Challenged Balb/C mice treated with HC030031.
Effects of HC-030031 were not limited to airway resistance. Similar to Trpa1-/- mice,
animals treated with the TRPA1 antagonist showed a significant decrease in transcription
of mucin by qPCR.
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Figure 7: Impaired induction of Mucin Transcription Balb/C mice treated with
HC-030031 during OVA-challenge. Relative quantities (RQ) of mucin5ac gene
transcript, determined by qPCR of whole mouse lung cDNA. GAPDH transcript levels
were used for normalization as an endogenous control. Animal groups: Trpa1+/+ OVA:
n = 4, Trpa1-/- OVA: n = 4, Trpa1 +/+ veh: n = 8, Trpa1-/- veh: n = 8. *, P < 0.05.

Trpa1 proinflammatory action is neurogenic
To investigate the possibility that TRPA1 acts within immune cells, gene expression was
evaluated in cDNA isolated from spleen, which includes a variety of immature immune
cells, Th2 cells, whole mouse lung and in leukocytes isolated from BALF. Minimal
transcription was noted except within DRG neurons further supporting the role of TRPA1
in neurogenic inflammation.
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Figure 8: Absence of Tpra1 expression outside of sensory neurons
Relative quantities (RQ) of Trpa1 gene transcript, determined by qPCR of cDNA isolated
from spleen , Th2 cells, leukocytes from BALF, whole lung, and DRG. GAPDH
transcript levels were used for normalization as an endogenous control. Animal groups:
n = 3-6 for all groups.

Additional studies were done with an Aspergillus model of asthma. This model,
consisting of a total of 6 intranasal administrations of Aspergillus protein extract. The
schedule of the model is summarized in the following figure.

SENSITIZATION

CHALLENGE

i.n. 50µg protein
Asp. extract

i.n. 25µg protein
Asp. extract

Day 0

Day 2

Day 4

14

Day 6

15

Lung function
BAL
Histology

16

HC-030031 IP
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Figure 9: Summary of Aspergillus Model
Mice were given 4 intranasal administrations of 50µg protein/40µl PBS every other day.
The mice were then given one week of rest after which they were given 2 intranasal
administrations of 25µg protein/40µl PBS on alternate days. HC-030031 was
administered starting with 160mg/kg on day 13 followed by 80mg/kg twice daily until
sacrifice.
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Figure 10: Diminished Leukocyte Infiltration in Aspergillus-Challenged Mice
Treated with HC-030031. Cell differentials from BALF from mice with and without
HC-030031 treatment demonstrating decreased eosinophilia. Animal groups: Veh: n = 6,
Asp-MC: n = 4, Asp-HC: n = 4.

*, P < 0.05.
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Figure 11: Treatment with HC-030031 reduced Aspergillus induced airway
hyperreactivity. Airway resistance as measured by Flexivent pulmonary mechanics
analyzer. Animal groups: Veh: n = 6, Asp-MC: n = 4, Asp-HC: n = 4. *p <0.05; ** p
<0.01
Notably, treatment with HC-030031 reduced airway resistance to the level of mice which
had never been exposed to Aspergillus.
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Figure 11: No significant difference in mice Diminished Leukocyte Infiltration in
Aspergillus-Challenged Mice Treated with HC-030031. Cell differentials from BALF
from mice with and without HC-030031 treatment demonstrating decreased eosinophilia.
Animal groups: Veh: n = 6, Asp-MC: n = 4, Asp-HC: n = 4.

25

*, P < 0.05.

Figure 12: Reduced Airway Hyperreactivty in Trpa1-/- mice. Airway resistance as
measured by Flexivent pulmonary mechanics analyzer. Trpa1+/+ Asp: n = 4, Trpa1-/Asp: n = 4, Trpa1 +/+ veh: n = 4, Trpa1-/- veh: n = 4.
While there is no statistically significant difference between the groups, there is a strong
trend showing reduced airway resistance among Trpa1 -/- mice.

26

Discussion
These findings illustrate the role of TRPA1 in the development of asthmatic
inflammation in an OVA albumin model of asthma. Preliminary findings suggest similar
responses in an Aspergillus based model of asthma. Trpa1-/- mice showed diminished
airway resistance, Th2 cytokines, and mucin synthesis compared to wild-type mice in an
OVA model. In addition to Trpa1-/- mice, pharmacological blockade also reduces airway
hyperreactivity, Th2 cytokines and mucin. Both small-molecule pharmacological
blockade of TRPA1 and genetic ablation of the channel both produce reduced asthma
susceptibility. This confirms that the anti-asthmatic response is due to inactivity of the
channel itself, not developmental defects associated with genetic deletion of Trpa1.
TRPA1 is a sensor of both exogenous and endogenous pro-inflammatory
molecules that are known to induce asthma. Exogenous activators include chlorine,
unsaturated aldehydes smoke, tear gas agents, and industrial isocyanates [53-56, 67].
Endogenous activators, including reactive oxidative species and lipid mediators, are
produced by infiltrating leukocytes and inflamed tissue and reach concentrations
sufficiently high to activate TRPA1 [61, 62, 68].
The mechanism of the anti-inflammatory effect (Figure 8) of TPRA1 blockade is
not certain, but is likely due to the reduction in the release of neuropeptides by sensory
neurons. Activation of TPRA1 by endogenous activators causes the release of
neuropeptides. These neuropeptides, including Neurokinin A, Substance P, and CGRP
act to produce microvascular changes including endothelial cell contraction and
upregulation of selectins and integrins. The expression of adhesion molecules, which are
complimentary to those on circulating leukocytes, mediates migration of inflammatory
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cells across the endothelium. Consequently, reduced activation of TRPA1 would
diminish neuronal excitation and a decrease in Ca2+ influx into sensory neurons. Data
from Dr. Marian Brackmann, not included here, found that levels of Neurokinin A,
Substance P, and GCRP were all significantly decreased in OVA treated Trpa1-/- mice
compared to OVA challenged wild type mice [69]. This finding is consistent with
reduced sensory neural activation.
Endogenous
activators:
4-HE, H2O2,
LO metabolites,
endocannabinoids

Endogenous
modulators:

TRPA1

PGE2, BK, NGF
histamin,
proteases,

Modified from Lee & Gu; Curr Opin Pharmacol. 2009

Figure 13: Mechanism of Neurogenic Inflammation in Airways
Activation of TRPA1 by endogenous agonists leads to neuropeptide release which leads
to subsequent microvascular leak, mucus hypersecretion and airway hyperreactivity.
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Earlier work by Hegde and coworkers [70] highlights the significance of
neuropeptides in the formation of lung inflammation. Substance P, through its action on
the Neurokinin-1 receptor, acts to induce changes that allow for increased post capillary
permeability, leukocyte infiltration and an increase in mucus secretions in the airways
[71]. Their work identified that by pharmacologic blockade of the Neurokinin-1 receptor
with SR140333 they could decrease measures of airway inflammation. They registered
significant decreases in neutrophil extravasation as measured by MPO activity, cytokine
release and the expression of cell adhesion molecules I-CAM1, V-CAM1, E-Selectin and
P-Selectin in lung in a bacterial sepsis model.
Neuropeptide release is reduced in mice with either genetically or
pharmacologically inactivated Trpa1, thereby reducing leukocyte infiltration and airway
hyperreactivity. Importantly, this study assessed whether this result could have been due
to the effects of TRPV1, another proinflammatory channel present in sensory neurons.
Given that neither genetic inactivation nor pharmacologic blockade of TRPV1 reduces
airway hyperreactivity, leukocyte infiltration, cytokine production or mucus production,
it is clear that the development of asthmatic inflammation is solely due to endogenous
activators of TRPA1 leading to an increase in the release of neuropeptides. While the
development of asthmatic inflammation is not a TRPV1 dependent event, this channel
may still be involved in the development of asthmatic symptoms secondary to airway
inflammation.
Despite encouraging evidence that asthma related mortality is decreasing, asthma
continues to pose a significant public health problem, and new methods of controlling the
disease are needed. The finding that TRPA1 is essential for the development of
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asthmatic inflammation in a murine model supports the idea that this channel represents a
mechanistic bridge between chemical and immunological stimuli in the airways. This
work also offers molecular insights into the pathway by which chemical exposures
exacerbate asthma. The identification of the role of TRPA1 as an important mediator of
asthmatic inflammation provides a novel pharmacologic target for the treatment of
asthma. While current TRPA1 antagonists are likely poor drug candidates for the
treatment of asthma because of their poor bioavailability, different formulations of this
class of compound, or chemically modified derivatives, may provide needed relief to the
asthmatics of the future.
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